(Q33269695)

24 July 2017

title

Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma (English)

1 reference

24 July 2017

0 references

1 reference

10

Dorothee von Laer

1 reference

24 July 2017

8

Heribert Knechten

0 references

Schlomo Staszewski

9

object named as

Schlomo Staszewski

0 references

Ursula Dietrich

object named as

Ursula Dietrich

12

0 references

Vicente Soriano

object named as

Vicente Soriano

6

0 references

author name string

Michael Humbert

1

1 reference

24 July 2017

Sascha Antoni

2

1 reference

24 July 2017

Boris Brill

3

1 reference

24 July 2017

Margot Landersz

4

1 reference

24 July 2017

Berta Rodes

5

1 reference

24 July 2017

Uwe Wintergerst

7

1 reference

24 July 2017

Heribert Knechten

8

1 reference

24 July 2017

Schlomo Staszewski

9

1 reference

24 July 2017

Matthias T Dittmar

11

1 reference

24 July 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

European Journal of Immunology

24 July 2017

published in

1 reference

24 July 2017

volume

37

1 reference

24 July 2017

issue

2

1 reference

24 July 2017

page(s)

501-515

1 reference

Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

HIV vaccine design and the neutralizing antibody problem

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

GP120: target for neutralizing HIV-1 antibodies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Identifying epitopes of HIV-1 that induce protective antibodies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Antibody protection: passive immunization of neonates against oral AIDS virus challenge.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Potent broad cross-neutralizing sera inhibit attachment of primary HIV-1 isolates (groups M and O) to peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Importance of B-cell responses for immunological control of variant strains of simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

HIV-specific IgG in cervicovaginal secretions of exposed HIV-uninfected female sexual partners of HIV-infected men.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

The immunology of HIV-infected long-term non-progressors--a current view.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Phage display technology: clinical applications and recent innovations

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Epitope identification and discovery using phage display libraries: applications in vaccine development and diagnostics

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Characterization of murine coronavirus neutralization epitopes with phage-displayed peptides

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

A mimotope peptide-based anti-cancer vaccine selected by BAT monoclonal antibody

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Mimotope vaccination for epitope-specific induction of anti-CD20 antibodies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Dissection of the humoral immune response toward an immunodominant epitope of HIV: a model for the analysis of antibody diversity in HIV+ individuals

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

3D-Epitope-Explorer (3DEX): localization of conformational epitopes within three-dimensional structures of proteins

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

AIDS vaccines: back to 'plan A'.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636560

7 January 2021

Identifiers

DOI

10.1002/EJI.200636560

1 reference

24 July 2017

1 reference